Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 132 (ZNF132)
- Target
- ZNF132
- Molecular classification
- Transcription factor, C2H2-type zinc finger protein
01
Overview
Zinc finger protein 132 is a member of the C2H2-type zinc finger family, containing 18 zinc finger motifs and acting primarily as a sequence-specific transcription regulator[2]. It is located on chromosome 19q13.4 and is characterized as a tumor suppressor in ESCC, where promoter methylation leads to gene silencing and increased cancer cell growth and invasion[2]. ZNF132 and the larger family of zinc finger proteins are implicated in essential cellular processes including transcriptional regulation, cell differentiation, DNA damage repair, and apoptosis[1][3][4]. There is limited direct functional characterization for ZNF132 outside its role in cancer and epigenetic regulation, but the protein's molecular features and family associations suggest broader biological significance. No drugs are clinically approved to target this molecule; research is ongoing regarding its biomarker potential in cancer[2][1][3][4].
- Other names
- ZNF132Zinc finger protein 132pHZ-12
02
Mechanism of action
For experimental drug interventions: restoring gene expression by promoter demethylation (reversal of epigenetic silencing)
03
Biological functions
Transcriptional regulationControl of cell proliferation, migration, invasion, apoptosis (based on experimental models in esophageal squamous cell carcinoma)Cellular differentiation
04
Disease associations
Cancer (specifically as a tumor suppressor in esophageal squamous cell carcinoma, and potentially in other solid tumors)Other roles in disease largely inferred from broader zinc finger protein family studies, including metabolism regulation, apoptosis, and immune response
05
Safety considerations
No specific safety concerns reported for targeting ZNF132; general risks relate to off-target effects of genome-modifying/epigenetic drugs
06
Interacting drugs
No FDA-approved drugs currently known to selectively target ZNF132.
1 more in the full profile.
07
Biomarkers
Promoter hypermethylation of ZNF132 is used as a biomarker for gene silencing and has potential utility in early cancer detection, especially in ESCC (esophageal squamous cell carcinoma)
Beyond the preview
Go deeper on Zinc finger protein 132 (ZNF132).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zinc finger protein 132 (ZNF132).